Reviva Pharmaceuticals Holdings, Inc. ( (RVPH) ) has released its Q4 earnings. Here is a breakdown of the information Reviva Pharmaceuticals Holdings, Inc. presented to its investors.
Reviva Pharmaceuticals Holdings, Inc. is a late-stage biopharmaceutical company focused on developing next-generation therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. The company is known for its innovative drug candidates, including brilaroxazine and RP1208, which are new chemical entities discovered in-house.
Reviva Pharmaceuticals recently announced its full-year 2024 financial results, highlighting significant progress in its clinical programs. The company’s lead candidate, brilaroxazine, has shown promising results in long-term safety and efficacy for treating schizophrenia, with plans to initiate a registrational Phase 3 trial in mid-2025.
Key financial metrics from 2024 include a net loss of approximately $29.9 million, an improvement from the previous year’s loss of $39.3 million. The company also reported cash and cash equivalents totaling $13.5 million at the end of 2024. Clinical highlights include positive data from the Phase 3 RECOVER study, demonstrating sustained efficacy and safety of brilaroxazine over one year.
Strategically, Reviva aims to submit a New Drug Application for brilaroxazine by the fourth quarter of 2026, with additional plans to explore partnership opportunities for its pipeline. The company also completed a public follow-on offering, raising approximately $18.0 million to support its ongoing initiatives.
Looking ahead, Reviva Pharmaceuticals is poised to advance its clinical programs and explore strategic partnerships, with a focus on addressing unmet medical needs in schizophrenia and other therapeutic areas. The management remains optimistic about the potential of brilaroxazine and is committed to achieving key milestones in the coming years.